CLINICAL TRIALS PROFILE FOR QSYMIA
✉ Email this page to a colleague
All Clinical Trials for qsymia
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00796367 ↗ | A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) | Completed | Medpace, Inc. | Phase 3 | 2008-12-01 | The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787). |
| NCT00796367 ↗ | A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) | Completed | VIVUS, Inc. | Phase 3 | 2008-12-01 | The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787). |
| NCT01834404 ↗ | Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 | 2013-04-01 | Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants. |
| NCT01834404 ↗ | Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients | Completed | Mayo Clinic | Phase 4 | 2013-04-01 | Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants. |
| NCT02229214 ↗ | Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects | Completed | VIVUS, Inc. | Phase 4 | 2014-08-01 | The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery. |
| NCT02301416 ↗ | Qsymia as an Adjunct to Surgical Therapy in the Superobese | Completed | VIVUS, Inc. | Phase 2 | 2014-12-01 | This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication. |
| NCT02301416 ↗ | Qsymia as an Adjunct to Surgical Therapy in the Superobese | Completed | Wake Forest University Health Sciences | Phase 2 | 2014-12-01 | This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for qsymia
Condition Name
Clinical Trial Locations for qsymia
Trials by Country
Clinical Trial Progress for qsymia
Clinical Trial Phase
Clinical Trial Sponsors for qsymia
Sponsor Name
